Novartis confirms 5 year milestone data for psoriasis treatment

Novartis confirms 5 year milestone data for psoriasis treatment
Credit: Shutterstock.com/ Hriana

Novartis has confirmed positive 5 year efficacy and safety results for Cosentyx from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis.

5 year Phase III data are a recognised milestone for assessing long-term efficacy and safety of innovative treatments.

“Cosentyx has consistently demonstrated sustained efficacy and safety providing psoriasis patients a new standard of long-term care,” said Vas Narasimhan, Global Head of Drug Development and Chief Medical Officer, Novartis.

He added: “With the first data from a pivotal trial with 5 years of follow up, Cosentyx continues to demonstrate it can provide what psoriasis patients want, a life with clear skin.”

4 year Phase III data presented at EADV 2016 showed Cosentyx delivered almost clear or completely clear skin in a majority of patients after 4 years of treatment.

The data showed that with Cosentyx, 97% of PASI 90 and 99% of PASI 100 response rates were maintained from Year 1 to Year 4.

Recently, new label updates announced for Cosentyx in Europe demonstrated long-term superiority of Cosentyx versus Stelara (ustekinumab) in moderate-to-severe plaque psoriasis on the basis of 52 week data from the CLEAR study, and expanded the use of Cosentyx for the treatment of moderate-to-severe scalp psoriasis.

Cosentyx was launched in 2015 as the first and only fully-human IL-17A inhibitor to treat psoriasis and is now licenced for the treatment of psoriatic arthritis and ankylosing spondylitis as well.

Psoriasis is a common, non-contagious, auto-immune disease that affects more than 125 million people worldwide.